Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Koninklijke Philips NV (PHG) Price & Performance

iShares iBoxx $ Inv Grade Corporate Bond ETFTrade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ Inv Grade Corporate Bond ETF vs Koninklijke Philips NV — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.88, while Koninklijke Philips NV trades at $26.61 (market cap $26.19B). The key difference: Koninklijke Philips NV pays a 3.79% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Koninklijke Philips NV is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

LQDPHG
52-Week High
$112.91$32.91
52-Week Low
$106.96$24.54
Market Cap
$26.19B
Sector
Health
Enterprise Value
$32.46B
Dividend Yield
3.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ Inv Grade Corporate Bond ETF

LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.

Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.

Koninklijke Philips NV

PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.

PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares iBoxx $ Inv Grade Corporate Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.

Read more on LQD

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG